Best of the Best 1675p £157m (LON:BOTB)
AGM Statement. Trading for the year to date has been stronger than expected at the time of the Company's final results (as announced on 15 June 2020). The momentum that built through the previous financial year has been maintained, resulting in a strong performance for the first four months of the new financial year and is expected to continue. This leads the Board now to expect both revenue and profits for the full year ended 30 April 2021 to be ahead of previous management expectations. As previously announced, the Company launched a new additional 'Midweek' car competition in May, alongside it's existing Dream Car and Lifestyle competitions. This, in combination with sustained investment in marketing and customer acquisition has delivered increased customer activity and a broader customer base. The Company also continues to reap the benefits of it's transformation to a wholly online operation. The Formal Sales Process continues,
Plus500 1469p £1.5bn (LON:PLUS)
The technology platform for trading Contracts for Difference ("CFDs") internationally, issued a trading update ahead of today's AGM, which is taking place at 10.00am BST.
The operational momentum achieved during H1 2020 has continued into the second half to date, with Plus500 making excellent progress across all key commercial and financial performance metrics. This performance has been primarily driven by the strength and differentiation of the Company's proprietary technology.
Revenue, in particular Customer Income, has remained strong in H2 2020 to date, supported by further growth in the Company's Active Customer base. The Company has also on-boarded a high level of new customers so far in the second half, driven by continued investment in its marketing technology, rapid response to market events and attractiveness of the Group's market-leading mobile and tablet offering.
FRP Advisory Group 122p £290.9m (LON:FRP)
FRP Advisory Group plc, a leading UK professional services firm specialising in restructuring advice, announced the acquisition of the JDC Group. Consideration compromises cash, founder deferred consideration and the issue of new ordinary shares for a total of £5.3 million plus a further payment contingent on the net assets of the JDC Group at completion of the transaction.
JDC Group is based in the Eastern region and comprises the operating businesses of JDC Corporate Finance and Walton Dodge Forensic. The JDC Group was founded in 2004 and is the leading specialist corporate finance and forensic services firm in the East of England. It is headquartered in Norwich with offices in Chelmsford and London. The firm's 4 Directors (Jon Dodge, Dave Howes, Chris Adlam and Fiona Hotston Moore) will join FRP as Partners along with all staff, including 10 further fee earners.
For the year to 31 March 2020, JDC Group unaudited revenues were £3.1 million and unaudited adjusted EBITDA was £1.2 million.
Pebble Group 87.5p £146.5m (LON:PEBB)
The provider of technology, services and products to the global promotional products industry, announces its results for the half year ended 30 June 2020. In H1 2020, Group revenue was £33.6m (H1 2019: £48.1m), generating adjusted EBITDA of £2.6m (H1 2019: £5.3m). Brand Addition's revenue reduced to £28.5m (H1 2019: £43.6m), primarily due to the impact on order demand within its Corporate Programme business, as lockdown restrictions severely affected clients' normal operations. Cost saving initiatives were implemented in the business which mitigated the impact on its profit, resulting in adjusted EBITDA of £0.4m (H1 2019: £3.3m). Facilisgroup performed strongly, proving its ability to deliver growth in revenue and profit in the most challenging market conditions. Revenue increased to £5.1m (H1 2019: £4.6m) and its ability to efficiently translate revenue into profits continued, with return on sales at 58% (H1 2019: 53%) and adjusted EBITDA of £2.9m (H1 2019: £2.4m).
“Whilst we do not expect a significant return of conferences or events until at least H2 2021, the current sales trend and the contracted, long-term nature of our client relationships give us confidence in the re-emergence of sales demand through 2021, where we are targeting a return towards 2019 levels.”
Futura Medical 16.75p £41.1m (LON:FUM)
HY June 20 Results•
MED3000 - a topical treatment for Erectile Dysfunction: In February 2020 Futura commenced formal proceedings for MED3000 to be approved as a medical device and clinically proven treatment for ED in Europe by an EU Notified Body.
· The European regulatory process for MED3000 remains on track with the company targeting a 2021 European approval date.
Post period—Meeting set for the third pre-submission meeting with the FDA before the end of October.
Significant progress also reported on TPR100 - Topical non-steroidal anti-inflammatory for the pain and inflammation associated with sprains, strains and bruises and soft tissue rheumatism and CBD100 - Futura's advanced proprietary DermaSys® formulation for transdermal delivery of Cannabidiol.
• £1.06 million net loss in the period (30 June 2019: net loss 4.46 million).
• In May 2020, the company received R&D tax credits of £2.22 million from HMRC with respect to the year ending 2019.
• Cash resources of 2.62 million at 30 June 2020 (30 June 2019: 5.63 million).
• The company continues to have sufficient cash resources through to Q2 2021 under current plans.
Global Petroleum 0.95p £1.93m (LON:GBP)
£1.4m raise at 0.75p. Proceeds from the Placing and Subscription will provide in full the funds needed for the work commitments (firm and contingent) in PEL 0029 during the remaining period of the Licence, and in PEL 0094 for the forthcoming exploration period to September 2021.
On 20 July 2020 Global announced an updated estimate of prospective resources for its licence PEL 0094, following its interpretation of the historic 3D seismic data over Block 2011A, which amounted to 687 MMbbl unrisked best estimate net prospective resources. It is the Company's intention to seek a farm-in partner for exploration drilling on PEL 0094, and potentially also to progress the work programme over the PEL 0029 area.
AEX Gold 45.5p £37.6m (LON:AEXG)
Update on its 2020 Summer Field Activities since mobilization in South Greenland on August 15th, 2020. · High-resolution aerial imagery drone has identified an outcropping Footwall Vein which lies an estimated 70-100 meters stratigraphically below the Main Vein on the north face of Nalunaq mountain. Historically, two drill holes have intersected a mineralised quartz vein at that level .
· AEX has so far drilled five holes at Nalunaq, for a cumulative 1,200 metres of drilling this field season. The first samples have been dispatched for assaying and the results of this will be announced once received
· GoldSpot Discovery Corp. has generated a preliminary list of additional targets for the wider regional exploration asset portfolio. These targets will be visited and prospected by our geologists in September 2020.
Igas Energy 12.65p £15.6m (LON:IGAS)
Agreement to acquire GT Energy UK Limited ("GT Energy"), a developer of deep geothermal heat projects onshore in the UK. The acquisition is in line with IGas's strategy of diversifying into the wider UK energy market whilst leveraging its core competencies as an UK onshore operator. Under the terms of the SPA, IGas will make an initial payment of £500,000 in shares. The maximum consideration payable to the Sellers under the SPA is £12 million and the ordinary shares of IGas which may be issued under the SPA shall not exceed Twenty-Nine Point Nine Per Cent (≤29.9%) of the fully diluted issued ordinary share capital of IGas.
GT Energy's principal project is a 14MW deep geothermal project in the Etruria Valley, Stoke-on-Trent. The project is anticipated to supply zero carbon heat to the city of Stoke-on-Trent on a long-term 'take or pay' contract ("TPA") with Stoke-on-Trent City Council ("SoTCC"). It is anticipated that the heat will be supplied through the SoTCC owned and operated district heating network, which is undergoing installation.
Immunodiagnostic Systems 240p £69.1m (LON:IDH)
The specialty solution provider to the clinical laboratory diagnostic market, announced the launch of four new i-Tracker® assays designed to run on its automated IDS-iSYS analyser. These assays were developed by partner Theradiag SA (Theradiag) and address the rapidly growing market of biologics drug monitoring.
The four i-Tracker® assays: i-Tracker® Infliximab, i-Tracker® Anti-Infliximab, i-Tracker® Adalimumab and i-Tracker® Anti-Adalimumab were previously launched on the 'i-Track10®' analyser, an instrument manufactured by IDS for Theradiag. In the six months since the Theradiag launch, the assays have undergone validation on the IDS-iSYS analyser and are now available for use on the installed base of IDS-iSYS analysers in Europe and other territories which accept a CE mark accreditation.
Seeing Machines 4.45p £149.75m (LON:SEE)
The advanced computer vision technology company that designs AI-powered operator monitoring systems to improve transport safety, announced today that its aftermarket driver monitoring technology, Guardian, has gathered over 5 billion kilometres of naturalist driving data, due to its extensive customer list globally.
A leader in driver monitoring technology across Automotive, Fleet/Off-road and Aviation transport sectors, Seeing Machines' access to this unique set of driving data is fundamental to its success and underpinned by Human Factors research, providing the platform from which the Company's automotive grade driver monitoring technology has been developed and refined.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.
0203 764 2344
Status of this Note and Disclaimer
This document has been issued to you by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific entity and is not a personal recommendation to anyone. Recipients should make their own investment decisions based upon their own financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, they have not been independently verified and are not guaranteed as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information in this document nor should it be relied upon as such.
Any and all opinions expressed are current opinions as of the date appearing on this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, directors, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document is sent to you as market commentary only. As market commentary this document does not constitute any of (i) investment research and financial analysis or other forms of general recommendation relating to transactions in financial instruments for the purposes of section B of annex I to Directive 2014/65/EU ("MIFID II Directive"); or (ii) investment research as defined in article 36(1) of Commission Delegated Regulation 2017/565/EU made pursuant to the MIFID II Directive; or (iii) non-independent research (as such term is defined in the Financial Conduct Authority's Conduct of Business Sourcebook).
This document should not be relied upon as being an independent or impartial view of the subject matter. The individuals who prepared this document may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority's Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as "relevant persons"). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority's Conduct of Business Sourcebook.
Neither this document nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.